Skip to main content
. Author manuscript; available in PMC: 2017 Sep 26.
Published in final edited form as: Cell Rep. 2017 Apr 4;19(1):101–113. doi: 10.1016/j.celrep.2017.03.038

Figure 1. Depletion of TAMs Increases γH2AX Levels in Response to Taxol Treatment.

Figure 1

(A) Preclinical trial design for combined CSF-1R inhibition and Taxol treatment in an orthotopic mouse model of breast cancer following mammary fad pad (MFP) injection of the TS1 tumor cell line and subsequent tumor establishment.

(B) Plot of tumor volume as a function of time. Treatment groups are vehicle (VEH) 20% Captisol, BLZ945 (BLZ), and Taxol (TAX). Vertical arrow indicates t = 0 when Taxol was administered. The vehicle was administered daily to all animals in the Taxol alone group.

(C) Quantification by image analysis of intratumoral CD68+ cells at 24, 48, and 72 hr after Taxol treatment.

(D–F) Quantitation of the percentage of (D) γH2AX+, (E) cleaved caspase-3+ (CC3+), and (F) Ki67+ cells within the tumor (left) and representative images of tumor sections (right). Scale bars, 50 μm. n = 5 mice in all treatment groups at all time points. All data are presented as mean ± SEM.

(C–F) Data are from whole tumors isolated at the indicated time points according to the trial design in (A).

Student’s t test was used to assess significance between treatment groups: *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S1.